Deka Biosciences is a biotech company led by entrepreneur Dr. John Mumm, who is backed by a team of experienced academic, biopharma and CDMO innovators with expertise in drug discovery, product development, characterization, and testing. Deka has developed disease specific Diakines™ designed to maximize patient benefits through improved pharmacokinetics / pharmacodynamics function by the targeted accumulation of dual and complimentary cytokines into affected tissues. Through developing a better understanding of each patient's immune response to different Diakines™, Deka hopes to maximize the impact of its Diakines™ by building specific targeted therapies for everyone.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/28/23 | $20,000,000 | Series B-2 |
Alexandria Venture Investments Amana Investments ATEM Capital Echo Investment Capital John Mumm Leaps by Bayer Lumira Ventures MPM BioImpact  Plains Venture Partners Viva BioInnovator | undisclosed |
